Clinical trials: Coronary Vessel
Coronary Artery Disease
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85.
- Trial name
- NCT00413647
- Testing
- CardioPET
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Coronary Disease
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after…
- Trial name
- (CAPP) (NCT01431495)
- Testing
- Pidogrel, Plavix
- Where
- Tunisia
- Volunteers
- 219 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Coagulation Defect; Bleeding
Quantra QPlus Sample Type Comparison
This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.
- Trial name
- NCT05290675
- Testing
- Quantra QPlus System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HemoSonics LLC
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Atrial Fibrillation
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi.
- Trial name
- X-TRA (NCT01839357)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 31 sites in Bulgaria, France and 5 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT)…
- Conditions
- Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
- Trial name
- NCT02744677
- Testing
- SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
- Where
- 27 sites in United States
- Volunteers
- 108 people
- Sponsor
- Edwards Lifesciences
Coronary Artery Disease
PRECISION GRX Registry
To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath GRX System, in the delivery and manipulation of coronary guidewires and stent/balloon…
- Trial name
- NCT03278301
- Testing
- Robotic-assisted PCI
- Where
- 20 sites in United States, Brazil and 2 more
- Volunteers
- 952 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Vasospastic Angina
A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of KFDA.
- Trial name
- STELLA (NCT02087007)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Peripheral Artery Disease
Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety
Based upon evidence of efficacy and safety of both cilostazol and probucol administration in independent randomized controlled trials in PAD and CAD, the present trial seeks to investigate the effect of concomitant administration…
- Trial name
- NCT01142284
- Testing
- Cilostazol, Probucol
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Myocardial Infarction
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute…
- Trial name
- NCT00168792
- Testing
- Tenecteplase, PCI
- Where
- 176 sites in United States, Austria and 16 more
- Volunteers
- 1,671 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
The Angioshield Study Feasibility II
Feasibility Study to Demonstrate the Safety of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery.
- Trial name
- NCT02543047
- Testing
- Angioshield
- Where
- Lithuania
- Volunteers
- 34 people
- Sponsor
- Neograft Technologies, Incorporated
Congestive Heart Failure, Ischemic Cardiomyopathy
Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity
The purpose of the present prospective, randomized study is to investigate the clinical effectiveness of standardized left ventricular reconstruction surgery (LVR).
- Conditions
- Congestive Heart Failure, Ischemic Cardiomyopathy, Coronary Artery Disease, Myocardial Diseases
- Trial name
- NCT00326690
- Testing
- Blue Egg Device
- Where
- 10 sites in United States, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioVentrix
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Unstable Angina, Myocardial Infarction
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]…
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Trial name
- NCT00093158
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 13,800 people
- Sponsor
- The Medicines Company
Cardiovascular Diseases, Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS)…
- Conditions
- Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease
- Trial name
- NCT05566678
- Testing
- Cigarette, THS, Smoking Abstinence
- Sponsor
- Philip Morris Products S.A.
Coronary Stenosis
Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA)
The objective of this study is to demonstrate safe and effective use of the Ringer perfusion balloon catheter for dilatation/pre-dilatation of coronary stenoses during percutaneous coronary intervention (PCI).
- Trial name
- NCT04862689
- Testing
- Ringer Perfusion Balloon Catheter
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Vascular Solutions LLC
Cardiovascular Diseases, Heart Diseases
Niacin Plus Statin to Prevent Vascular Events
The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease
- Trial name
- NCT00120289
- Testing
- Extended release niacin, Simvastatin
- Where
- 91 sites in United States, Canada
- Volunteers
- 3,414 people
- Sponsor
- Axio Research. LLC
Coronary Artery Disease
Vascular Implant Safety and Efficacy Study
Assessment of the safety and clinical performance of a coronary stent system in de novo coronary artery lesions
- Trial name
- BIOVITESSE (NCT03263858)
- Testing
- Stent
- Where
- 5 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Biotronik CRC Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.